AzTrials
AzTrials

Dry Eye DiseaseMAOS-SNCT04235400

Multimodal Screening of Dry Eye Disease

An observational study of Dry Eye Disease, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Two methods allow to evaluate tear breakup time (BUT): without prior dye instillation (No Dye BreakUp Time NDBUT) or after fluorescein instilation (FBUT). The interconnections between those two values are unknown Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Dry Eye Disease
What is being tested?
No Dye BreakUp Time
How many people
60 participants
Where
1 siteFrance
Study dates
28 Jan 2021to Mar 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Major patients consulting for dry eyes or requiring dry eye screening

Who may be able to join

  • adult patient (age >18 yo),
  • known allergy to topical fluorescein
  • Patient informed of the study who gave it's non-opposition to participate

Who cannot join

  • Ocular surgery (including punctal plugs surgery) within the 3 previous months
  • contact lens wearing within the 3 previous months
  • Patient under guardianship or convicted person
  • pregnant woman

Trial locations and contacts

1 site in 1 country.

Marc LABETOULLE, Pr contact

33 1 45 21 36 90

marc.labetoulle@aphp.fr

Anne-Laurence BEST, Dr contact

bestanlo@hotmail.com

France1 site, 1 recruiting
  • Opthtalmology Departement, Bicêtre Hospital

    Le Kremlin-Bicêtre, Val De Marne, 94275

    Marc LABETOULLE, Pr, 33 1 45 21 36 90, marc.labetoulle@aphp.fr

    Recruiting

Other trials in France

About this study

Official title: Multimodal Analysis of Ocular Surface for Screening Dry Eye Disease

Two methods allow to evaluate tear breakup time (BUT): without prior dye instillation (No Dye BreakUp Time NDBUT) or after fluorescein instilation (FBUT). The interconnections between those two values are unknown

Read the detailed description

To date, there are a limited numbers of tests available for screening ocular dryness:

  1. assessement of tear production through Schirmer's test (paper strips are inserted into the eye for 5 minutes to measure the production of tears: normal value is superior to 15 mm wetting of the paper after 5 minutes, pathologic if inferior to 5-10 mm) ii) assessment of the ocular surface damage after instillation of fluorescein (presence of punctuate superficial lesions on the corneal and conjunctival epithelium) the with the slit lamp + blue filter iii) assessment of the FBUT (measurement of the tear breakup time after fluorescein dye instillation): normal value is superior to 15 seconds, pathologic value inf inferior to 5-10 seconds iv) assessment of the inflammation of eyelids (with the slit lamp). These diagnostic tests are used in everyday clinical practice, but however the international consensus conference (Dry Eye Workshop II, 2017) clearly recommended that, whenever practicable, some other tests must be carried out to optimize the efficacy the diagnostic procedure of dry eye disease. This is the case for the NDBUT (in opposition to the FBUT which uses fluorescein), the tear meniscus height (TMH) which give an rapid hint on the quantity of tears present on the ocular surface, the measure in real time of the tear osmolarity and, at last, the analysis of the thickness of the tear's layer by interferometry (measurement of the light fringes reflected by the tears when illuminated with polarized light, whereby the complete layer or the lipid layer alone can be evaluated separately depending on the machines used) and of the assessment of the quality of the Meibomian glands (non-contact imaging by infrared illumination).

All these techniques are recommended for the detection and the analysis of the mechanism inducing ocular dryness because they are non-invasive and painless. They also are recommended to be carried out jointly because there is still no single objective criterion that is sufficiently robust to be used alone to make this diagnosis, which is therefore ultimately based on an overall analysis of these various parameters.

Furthermore, the nature of the relationships between these different objective diagnostic tests remains still poorly understood.

One of the least well elucidated points in this respect is the relationship between the FBUT and the NDBUT, the latter having the theoretical advantage of being less subjective (the measurement is made by a medical device that detects the deformation time of a light test pattern projected onto the tear film). This method therefore tends to measure rather the moment when the film becomes thinner (generating the deformation of the test pattern), whereas the measurement of FBUT (i.e. after instillation of fluorescein), is certainly subjective but it measures the real tear break time, which corresponds physiologically to a critical moment (regulated by the blink reflex when sensitivity is normal). A retrospective study, carried out in patients known to suffer from dry eye disease and using many of the same instruments as those to be used in the present study, suggested that the NDBUT is generally longer than the FBUT (with an increasing difference with the values), which could be considered paradoxical (the thinning being expected to precede the complete rupture). This relationship must therefore be studied prospectively to analyze the nature of this difference (correlation?) and its relationship with other markers of dry eye disease.

The level of subjective symptoms and the impact on the quality of life felt by the patient will be recorded in order to explore whether the possible difference between NDBUT and FBUT is correlated with the intensity and/or frequency of the symptoms felt.

Conditions
Dry Eye Disease
Being tested
No Dye BreakUp Time
Keywords
dry eye, TBUT, NIBUT
Medical subject headings
Dry Eye Syndromes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No Dye BreakUp TimeDiagnostic test

    Measurement without dye of the tear meniscus height (TMH) which give an rapid hint on the quantity of tears present on the ocular surface, the measure in real time of the tear osmolarity and, at last, the analysis of the thickness of the tear's layer by interferometry (measurement of the light fringes reflected by the tears when illuminated with polarized light, whereby the complete layer or the lipid layer alone can be evaluated separately depending on the machines used) and of the assessment of the quality of the Meibomian glands (non-contact imaging by infrared illumination).

Study groups in NCT04235400
Study groupRoleWhat they receive
patient with dry eye diseaseNot described
Receives: Diagnostic Test: No Dye BreakUp Time

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. results of the NDBUT and FBUT

    analysis of the interconnections between the measure of the tear breakup time without adjunction of dye and measure obtained after instillation of the dye (fluorescein)

    Measured: at the end of the study (1year)

Secondary outcomes (10)
  1. Ocular Surface Disease Index (OSDI) questionnaire results

    to assess the symptoms of ocular dryness

    Measured: at day 1

  2. visual analogic scale (EVA) for the assessment of the impact of the dry eye for the patient

    0 means no impact, 100 means total impact of the disease

    Measured: at day 1

  3. Tear meniscus height

    with the LACRYDIAG device

    Measured: at day 1

  4. Results of the tears interferometry with the LACRYDIAG device

    Measured: at day 1

  5. Results of the tears interferometry with the LIPIVIEW device

    Measured: at day 1

  6. Results of the meibography with the LIPIVIEW device

    Measured: at day 1

  7. Thickness of the lipidic layer measured with LIPIVIEW device

    Measured: at day 1

  8. Tear osmolarity

    normal osmolarity is about 290 milliosmol per liter (mOsm/l). An elevated reading, >313 mOsm/L indicates hyperosmolarity, and thus the loss of homeostasis leading to dry eye disease

    Measured: at day 1

  9. Quality of the corneal epithelium (after fluorescein instillation, Oxford scale)

    Measured: at day 1

  10. Tear's production measured by Schirmer I test

    normal value is superior to 15 mm wetting of the paper after 5 minutes, pathologic if inferior to 5-10 mm

    Measured: at day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2020
  2. Study start28 Jan 2021
  3. Primary completionJan 2023 (estimated)
  4. Study completionMar 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04235400
Sponsor's protocol ID
APHP191122
Other IDs
2019-A03086-51
Acronym
MAOS-S
Status last verified
Sep 2022
First submitted
17 Jan 2020
Last updated
7 Sep 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Dry Eye Disease, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Marc LABETOULLE, Pr (33 1 45 21 36 90, marc.labetoulle@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

results of the NDBUT and FBUT (time frame: at the end of the study (1year)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in